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        The tumor suppressor gene   CYLD   was identi-
fi  ed in patients with familial cylindromatosis, 
which is an autosomal dominant predisposition 
to multiple neoplasms of the skin appendages. 
The tumors are believed to arise from the ec-
crine or apocrine cells of the skin (  1  ). Approx-
imately 70% of the cylindromas exhibit loss of 
heterozygosity on chromosome 16q containing 
the   CYLD   gene (  2  –  6  ). 
  Sequence analysis of the   CYLD   gene pre-
dicts a protein with several functional domains, 
including three CAP-Gly domains and a de-
ubiquitination domain at the C terminus (  7  –  9  ). 
In vitro studies showed that CYLD contains 
binding sites for TRAF2 and NEMO (  7  ), and 
that the deubiquitinating activity of CYLD is 
directed to lysine 63 (K63)  –  linked ubiquitin 
(Ub) (  7  ). Linkage of Ub through K63 assembles 
a new molecular platform, allowing the recruit-
ment of proteins involved in signal transduction 
(  10  –  12  ), whereas Ub chains linked through K48 
destine proteins for proteasomal degradation 
(  13, 14  ). Suppression of CYLD expression by 
RNA interference causes an increase in the ac-
tivity of the transcription factor NF-    B, which 
is activated by TNF     signaling, thus inhibiting 
apoptosis (  7, 8, 15  ). The increase of NF-    B 
activation in CYLD knockdown cells was at-
tributed to defective removal of K63 Ub chains 
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  B cell homeostasis is regulated by multiple signaling processes, including nuclear factor-    B 
(NF-    B), BAFF-, and B cell receptor signaling. Conditional disruption of genes involved in 
these pathways has shed light on the mechanisms governing signaling from the cell surface 
to the nucleus. We describe a novel mouse strain that expresses solely and excessively a 
naturally occurring splice variant of CYLD (  CYLD  ex7/8     mice), which is a deubiquitinating 
enzyme that is integral to NF-    B signaling. This shorter CYLD protein lacks the TRAF2 
and NEMO binding sites present in full-length CYLD. A dramatic expansion of mature B 
lymphocyte populations in all peripheral lymphoid organs occurs in this strain. The B 
lymphocytes themselves exhibit prolonged survival and manifest a variety of signaling 
disarrangements that do not occur in mice with a complete deletion of   CYLD  . Although 
both the full-length and the mutant CYLD are able to interact with Bcl-3, a predominant 
nuclear accumulation of Bcl-3 occurs in the CYLD mutant B cells. More dramatic, however, 
is the accumulation of the NF-    B proteins p100 and RelB in   CYLD  ex7/8     B cells, which, 
presumably in combination with nuclear Bcl-3, results in increased levels of Bcl-2 expres-
sion. These fi  ndings suggest that CYLD can both positively and negatively regulate signal 
transduction and homeostasis of B cells in vivo, depending on the expression of CYLD 
splice variants. 2616 ROLE OF CYLD IN B CELLS | H  ö  velmeyer et al.
from TRAF2 and NF-    B essential modulator (NEMO) by 
CYLD (  7  –  9  ). 
  In a mechanistically analogous manner to its eff  ect on 
TRAF2, CYLD was found to inhibit signaling from Toll-
like receptor 2 (TLR2) by removing K63-linked Ub from 
TRAF6 and TRAF7 (  16  ). Interestingly, it was shown that 
after TLR2 activation, CYLD inhibits the phosphorylation 
of TRAF6 and TRAF7, which, in turn, suppresses MKK3 
and MKK6, leading to reduced MAP kinase p38 phosphoryl-
ation (  17  ). In addition to p38 signaling, CYLD negatively 
regulates the stress-activating MAP kinase family, the JNK 
kinases. CYLD inactivation resulted in hyperactivation of JNK 
upon TNF    , IL-1    , LPS, and anti-CD40 treatment (  17  ). 
This hyperactivation is believed to be a result of negatively 
regulating the activation of MKK7, which is the kinase res-
ponsible for JNK activation (  17  ). 
  To investigate the physiological role of CYLD in vivo, 
we generated mouse strains with targeted modifi  cations in 
the   CYLD   gene. In addition to a complete knockout of   CYLD  , 
exon 7 of the   CYLD   gene was fl  anked by   loxP   sites in a second 
mouse strain to result in conditional, excessive, and solitary 
expression of a shorter splice variant of the CYLD protein, 
hereafter termed sCYLD. The sCYLD protein is devoid of 
both TRAF2 and NEMO binding sites. In this article, we 
present data describing the profound alterations in the immune 
system of these mice (  CYLD  ex7/8    ), which is characterized by 
lymphomegaly and splenomegaly and a striking increase in B 
cell numbers. Overexpression of sCYLD further bestows B 
lymphocytes with increased IgG1 production and enhances 
survival capabilities of the B cell. 
    RESULTS   
  Generation of   CYLD  ex7/8     mutant mice 
  CYLD mutant mice were generated applying standard gene-
targeting techniques in mouse embryonic stem cells (Fig. 
S1, available at http://www.jem.org/cgi/content/full/jem
.20070318/DC1). Using   Cre/loxP   technology, three diff  er-
ent mouse strains were generated. The fi  rst strain,   CYLD  neo    , 
contains the neo resistance gene upstream of exon 7, decreasing 
transcription of   CYLD   (Fig. S1). The second strain,   CYLD  FL    , 
harbors two   loxP   sites fl  anking exon 7 of   CYLD   (Fig. S1). 
Finally,   CYLD  ex7/8     mice lacking exon 7 after Cre-mediated 
  Figure 1.     The identifi  cation of a new splice variant of CYLD. 
(A) Schematic representation of exons 6  –  9 of the   CYLD   gene, with respec-
tive transcripts. (B) RT-PCR of cDNA generated from MEFs of the indi-
cated genotypes using primer pair P1 and P2. WT full-length CYLD 
transcript corresponds to the 770-bp band, whereas the alternatively 
spliced CYLD transcript is 244 bp. Bands were isolated, subcloned, and 
verifi  ed by sequencing. The intermediate band could be determined as 
an unspecifi  c band. (C) Western blot analysis of lysates from WT tissue 
and cells. (lane 1) Spleen; (lane 2) T cells; (lane 3) LNs; (lane 4) thymus; 
(lane 5) B cells. Actin was used as loading control. (D) Western blot 
analysis of lysates from WT and   CYLD  ex7/8    B cells using anti-CYLD anti-
body. Actin was used as loading control. (E) Schematic representation 
of the different CYLD constructs used for transfection experiments in 
HeLa cells. Highlighted are the important domains of CYLD. FL-CYLD 
(full-length CYLD), C/S-mut CYLD (full-length CYLD carrying a mutation 
from C to S to generate a catalytically inactive form), and sCYLD alter-
natively spliced CYLD lacking exons 7 and 8. (F) HeLa cells were trans-
fected with plasmids encoding either His-FL-CYLD or for His-sCYLD 
together with either plasmid pcDNA or plasmid encoding for TRAF2. 
Transfected cells were lysed and coimmunoprecipitated with anti-His 
antibody for CYLD, separated on an 8% SDS-PAGE, and transferred to 
PVDF membrane. The membranes were incubated with TRAF2 and CYLD 
antibodies, respectively. (G) MEFs were transfected with TRAF2-FLAG 
cDNA and TRAF2 was immunoprecipitated with anti-FLAG antibody. 
Thereafter, TRAF2 was separated on a 4  –  12% SDS-PAGE and transferred 
to PVDF membrane. The membrane was incubated with Ub-specifi  c 
antibody. (lane 1) Mock-transfected WT MEFs; (lane 2) WT MEFs trans-
fected with TRAF2-FLAG; (lane 3)   CYLD  ex7/8    MEFs transfected with 
TRAF2-FLAG. Data presented are representative of three different 
experiments. (H) HeLa cells were transfected with the indicated CYLD con-
struct encoding plasmids together with plasmids coding for Flag-Bcl-3 
and His-Ubiquitin. Protein lysates of transfected cells were used for 
immunoprecipitations with anti-His antibody, and Western blots were 
incubated with antibodies against the His and the Flag tags. Flag-Bcl-3 
was used as a loading control for the Bcl-3 levels in the different 
cell types.     
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  Lymphoid system defects in   CYLD  ex7/8     mice 
    CYLD  ex7/8     mice exhibited considerably larger spleens, LNs, and 
Peyer  ’  s patches (  Fig. 2 A   and not depicted).   Careful micro-
scopic examination revealed a disorganized structure of the 
spleen, where the distinct B cell and T cell zones of the follicle 
were not uniform as in WT spleens (  Fig. 2 B  ). Importantly, 
such abnormalities of the secondary immune organs were not 
reported in mice with complete inactivation of the   CYLD   
gene (  18  ) (unpublished data). 
  The   CYLD  ex7/8     mice displayed massively enlarged sec-
ondary lymphoid organs as early as 4 wk of age, whereas other 
tissues appeared normal (unpublished data). To investigate the 
mechanisms underlying these enlarged lymphoid organs, we 
examined lymphocyte populations of BM, spleen, LNs, and 
peritoneal cavity (PC). Analysis of B220     cells in the BM of 
  CYLD  ex7/8     mutant mice shows a small decrease in the per-
centage of the immature B lymphocyte compartments (  Fig. 
3 A  , top).   To analyze early B cell development, B220    IgM    −    
cells were analyzed for the expression of the pro-B cell marker, 
c-Kit. We observed an increase in the pro-B cell fraction, in-
dicating that deletion of the FL-CYLD leads to a partial block 
in early B cell diff  erentiation (  Fig. 3 A  , bottom). 
  Strikingly,   CYLD  ex7/8     mice, but not heterozygous and 
control mice, demonstrate a dramatic accumulation of B cells 
in all secondary lymphoid organs tested (  Fig. 3 B   and   Table I  ; 
not depicted for Peyer  ’  s patches).   The proportion and ab-
solute number of immature B cells was reduced in   CYLD  ex7/8     
mice (  Fig. 3 C   and   Table I  ), although they displayed signifi  -
cantly higher total B cell numbers (  Table I  ). 
  As seen in   Fig. 3 D   and   Table I  , the proportion, as well as 
the absolute number, of marginal zone (MZ; CD21  high  CD23  low  ) 
recombination through transient transfection of the targeted 
embryonic stem cells with a Cre-expressing plasmid (Fig. S1). 
  CYLD  ex7/8     mice were born at the expected Mendelian fre-
quencies and survived normally when housed under pathogen-
free conditions. 
  Germline deletion of exon 7 should lead to splicing from 
exon 6 to 8 resulting in an out-of-frame translation of CYLD 
(  Fig. 1 A  ).   RT-PCR was applied to cDNA from mouse em-
bryonic fi  broblasts (MEFs) of the indicated genotypes us-
ing primers located in exon 6 and 9 of the CYLD transcript 
to verify the absence of the WT allele in   CYLD  ex7/8     MEFs. 
This analysis revealed an unexpected shorter amplifi  ed prod-
uct besides the expected band from the full-length transcript 
(FL-CYLD) in WT MEFs. This shorter product represents 
an alternative splice variant of CYLD lacking exons 7 and 8, 
termed sCYLD.   CYLD  ex7/8     MEFs are devoid of the full-
length transcript, but express the sCYLD splice variant exces-
sively (  Fig. 1 B  ). Using CYLD-specifi  c antibodies, sCYLD 
protein could be detected in diff  erent tissues and cells of WT 
animals (  Fig. 1 C  ). To investigate whether deletion of WT 
CYLD (FL-CYLD) in   CYLD  ex7/8     mice results in higher ex-
pression levels of sCYLD, protein extracts were prepared from 
purifi  ed B cells of WT and   CYLD  ex7/8     mice, revealing high 
expression of sCYLD in   CYLD  ex7/8     cells compared with WT 
cells (  Fig. 1 D  ). 
  Previously, CYLD was identifi  ed as a deubiquitinating 
enzyme, removing K63-conjugated Ub molecules from TRAF2, 
TRAF6, and NEMO (  7  –  9  ). However, the putative TRAF2 
and NEMO binding sites are absent in the sCYLD protein 
(  Fig. 1 E  ). To verify whether sCYLD is, indeed, unable to 
bind TRAF2, HeLa cells were transfected with expres  sion 
plasmids encoding either FL-CYLD or sCYLD together with 
TRAF2-encoding or control plasmids. As shown in   Fig. 1 F  , 
FL-CYLD protein, but not sCYLD, coimmunoprecipitated 
with TRAF2, indicating that in contrast to FL-CYLD, 
sCYLD does not bind TRAF2. However, in an 8% SDS-
PAGE, the diff  erence in size between FL-CYLD and sCYLD 
could not be unambiguously demonstrated (  Fig. 1 F  ). In 
agreement, immunoprecipitated TRAF2 from extracts of 
  CYLD  ex7/8     MEFs was highly ubiquitinated compared with 
TRAF2 immunoprecipitated from WT cells (  Fig. 1 G  ). 
To investigate whether sCYLD is still able to function as 
a deubiquitinating enzyme, similar transfection experiments 
were applied to determine whether both CYLD proteins 
are capable of removing K63-conjugated Ub from Bcl-3, 
which is a novel substrate for CYLD (  18  ). The Bcl-3 bind-
ing site in CYLD is predicted to reside outside the area 
absent in sCYLD (  Fig. 1 E  ). We cotransfected HeLa cells 
with expression vectors encoding His-tagged Ub and Flag-
tagged Bcl-3, together with plasmids coding either for 
FL-CYLD, or for a catalytically inactive form of CYLD 
(C/S-CYLD) or for sCYLD.   Fig. 1 H   shows that both 
sCYLD and FL-CYLD are able to remove Ub from Bcl-3. 
Collectively, our results demonstrate that sCYLD is not able 
to deubiquitinate TRAF2, but still removes K63-linked Ub 
from Bcl-3. 
  Figure 2.     Enlarged spleen and Peyer  ’  s patches (PP) in   CYLD  ex7/8    
mice. (A) Spleens and PP dissected from WT and   CYLD  ex7/8    mice were com-
pared. Ruler indicates the size of the organs (centimeters). (B) Cryostat 
sections from WT and   CYLD  ex7/8    spleens were immunostained for B and 
T cell follicles with anti-B220 (blue) and anti-CD3     (brown). Bars, 500    m .    2618 ROLE OF CYLD IN B CELLS | H  ö  velmeyer et al.
B cell region located outside of the MOMA1     cells corre-
sponding to the MZ B cells was larger in the mutant spleens 
compared with controls (  Fig. 3 E  ). Interestingly, the ex-
pansion of MZ and follicular B cells was accompanied by 
a decrease in the proportion and absolute number of B-1a 
(CD19  high  CD5    CD23    	   ) and B-1b (CD19  high  CD5    	   CD23    	   ) 
B cells in the PC (  Fig. 3 F   and   Table I  ). These results suggest 
that either overexpression of sCYLD or disruption of FL-
CYLD is critical for regulating the maturation of BM B cells 
and the distribution of peripheral B cells. 
  To address whether these diff  erences in the B cell com-
partment resulted from the overexpression of sCYLD, we 
analyzed another CYLD mutant strain,   CYLD  ko    , in which the 
neomycin resistance gene was introduced into the fi  rst coding 
exon of the   CYLD   gene, thus preventing its expression (  18  ). 
and follicular (CD21  in  CD23  lo  ) B cells were increased by two- 
to threefold in   CYLD  ex7/8     mice compared with WT mice. 
Interestingly, expression of CD21 and CD23 by B cells iso-
lated from   CYLD  ex7/8     mice was elevated compared with con-
trol B cells (  Fig. 3 D  ). The latter was accompanied by an 
increase in cell size of the CYLD mutant B cells (unpub-
lished data). To analyze the structure of MZ B cells, spleen 
sections from   CYLD  ex7/8     and littermate control mice were 
stained with anti-MOMA1 antibody, which binds to me-
tallophilic macrophages, marking the border of the MZ. 
As shown in   Fig. 3 E  , MOMA1     cells can be detected in 
the spleens of   CYLD  ex7/8    ; however, the MZ appeared to be 
disordered and discontinuous compared with WT spleens. 
Furthermore, the amount of MOMA1     cells was increased 
without forming a closed ring around the follicle.   Notably, the 
  Figure 3.     B cell populations in   CYLD  ex7/8    mice. Flow cytometry of 8-wk-old WT,   CYLD  ex7/8   , and   CYLD  ex7/8;wt    littermate controls stained with the indi-
cated antibodies. (A) Analysis of BM populations. (bottom) Cells gated on IgM    	    lymphocytes. (B) Analysis of B/T cell ratio in spleen (Sp) and inguinal LNs 
(LN). (C) Decreased percentage of immature (CD21  low HSA high  ) B cells in spleens of   CYLD  ex7/8    mice. Shown are cells gated on CD19     lymphocytes. (D) In-
creased percentage of MZ (CD21  high CD23 low  ) B cells in   CYLD  ex7/8    spleens. Cells were gated on CD19     lymphocytes. (bottom) The mean fl  uorescence inten-
sity of CD23 and CD21 expression of WT and   CYLD  ex7/8    B cells. (E) Histological analysis of spleen sections from   CYLD  ex7/8    and WT mice using MOMA1 (blue) 
and IgM antibody (brown). (top) 10  
   magnifi  cation; (bottom) 20  
   magnifi  cation. Bars: (top) 400     m; (bottom) 100     m. (F) B cells isolated from the PC 
were analyzed for B-1 and B-2 B cell populations. Cells were gated on CD19     B cells. In all graphs, data are representative of fi  ve independent experi-
ments with fi  ve mice of each genotype. Data are shown for cells gated on the lymphocyte gate, excluding dead cells using Topro3. Numbers in the graphs 
indicate the percentage of cells from the gated population.     JEM VOL. 204, October 29, 2007 
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harbor a relatively high number of NP-specifi  c precursor 
cells (    1%) (  19  ). To test whether these fi  ndings hold true 
for another TD antigen with lower precursor frequency, we 
immunized mice with KLH.   CYLD  ex7/8     mice developed sig-
nifi  cantly higher levels of KLH-specifi  c IgG1 antibodies after 
immunization compared with WT mice (Fig. S3 A, available 
at http://www.jem.org/cgi/content/full/jem.20070318/DC1). 
  CYLD  ex7/8     mice and littermate controls were also immunized 
with the T cell  –  independent (TI) antigen NP-Ficoll, result-
ing in similar levels of NP-specifi  c IgM and IgG3 antibodies 
in   CYLD  ex7/8     and WT mice (  Fig. 4 C  ). 
  To examine whether the high IgG1 antibody levels ob-
served in nonimmunized mice, as well as in the immunized 
mutant mice, were a consequence of increased antibody pro-
duction by plasma cells or whether   CYLD  ex7/8     B cells switch 
more effi   ciently to other antibody classes, B cells from WT 
and   CYLD  ex7/8     mice were isolated and, subsequently, incu-
bated for 5 d ex vivo with optimal concentrations of LPS and 
IL-4. A higher proportion of CYLD mutant B cells switched 
to the IgG1     isotype compared with WT B cells (Fig. S3 B). 
B cells in the Peyer  ’  s patches are constantly encountered 
by the gut fl  ora, and therefore yield higher proportions of 
class-switched B cells. Peyer  ’  s patches from   CYLD  ex7/8     mice 
contain a threefold increased B cell population rich in 
IgG1-expressing B cells compared with WT mice (  Fig. 4 D  ). 
Additionally, these results were strengthened by an increased 
proportion of PNA    Fas     B cells in   CYLD  ex7/8     Peyer  ’  s patches, 
which is indicative of germinal center B cells (  Fig. 4 E  ). The 
hyper TD antigen-specifi  c response observed in   CYLD  ex7/8     
mice suggests that sCYLD is important for negatively regu-
lating TD, but not TI, responses. 
  The B cell phenotype in   CYLD  ex7/8     mice is B cell intrinsic 
  As all cells in   CYLD  ex7/8     mice lacked exon 7, it was unclear 
whether the defect in B cells was intrinsic to B cells or secondary 
Fig. S2 A (available at http://www.jem.org/cgi/content/
full/jem.20070318/DC1) shows that the B cell development 
in the BM was unchanged in   CYLD  ko     mice. Furthermore, 
in contrast to   CYLD  ex7/8     mice,   CYLD  ko     mice showed nei-
ther diff  erences in B/T cell ratio nor an elevation of MZ 
and follicular B cells in the spleen nor a decrease of B-1 B 
cells in the PC (Fig. S2, B  –  D). Moreover, B cell numbers in 
these mice were comparable to WT B cell numbers (  Table I  ). 
Thus, we conclude that the absence of the FL-CYLD, in 
tandem with the overexpression of sCYLD, is responsible for 
the increased proportion of B cells in the lymphoid organs of 
  CYLD  ex7/8     mice. 
  Skewed humoral immune response of   CYLD  ex7/8     mice 
  To determine whether the expansion of B cells in   CYLD  ex7/8     
mice affects the immune response, we evaluated serum 
antibody levels in   CYLD  ex7/8     and WT mice. The sera of 
  CYLD  ex7/8     mice contained signifi  cantly lower IgM and IgG3 
antibody titers compared with WT littermates, whereas all 
other tested antibody classes, including IgG1, IgG2a, IgG2b, 
and IgA, were elevated in   CYLD  ex7/8     mice (  Fig. 4 A  ).   The 
latter antibody isotypes are more frequently secreted by class-
switched B cells after encountering T cell  –  dependent (TD) 
antigens. Therefore, we next investigated TD antigen re-
sponses of   CYLD  ex7/8     B cells and control B cells. To this end, 
mice were challenged with nitrophenol-conjugated chicken 
    -globulin (NP-CG) and immune responses were measured 
by ELISA. Upon in vivo challenge with NP-CG,   CYLD  ex7/8     
mice developed signifi  cantly lower antibody titers of both IgM 
and IgG3 isotypes, whereas secretion of NP-specifi  c IgG1 
and IgG2a antibodies was enhanced compared with WT 
mice (  Fig. 4 B  ). In addition,   CYLD  ex7/8     mice developed 
higher titers of NP-specifi  c Ig     antibodies, whereas the NP-
specifi  c Ig     antibody levels were similar to the levels in WT 
mice (  Fig. 4 B  , top). Previously, it was shown that WT mice 
  Table I.      Lymphocyte population sizes 
  Spleen 
Genotype Total B cells Immature MZ
     WT (  14  ) 79.4 (8.2) 46.7 (4.8) 7.7 (0.8) 2.4 (0.3)
     CYLD  ex7/8;wt   (  9  ) 96.9 (13.0) 49.3 (6.6) 6.2 (0.9) 2.9 (0.4)
     CYLD  ex7/8   (  14  ) 138.7 (21.6)    a   111.1  (17.3)    b   4.8  (0.7)    a   10.3  (1.6)    b   
     CYLD  ko   (  5  ) 84.7 (8.4) 42.4 (4.1) 14.4 (1.4) 4.6 (0.4)
     CD19-Cre/CYLD  FL/FL   (  5  ) 134.5 (12.6)    a   100.8  (9.5)    a    11.1 (1.0) 10.1 (0.9)    a   
Peritoneal cavity
Genotype B-1 B-2
     WT (  4  ) 1.4 (0.3) 0.9 (0.2)
     CYLD  ex7/8;wt   (  4  ) 1.1 (0.1) 1.6 (0.1)
     CYLD  ex7/8   (  4  ) 0.3 (0.2)    a   2.1  (0.2)    a   
     CYLD  ko   (  5  ) 1.5 (0.3) 0.3 (0.1)
     CD19-Cre/CYLD  FL/FL   (  5  ) 0.4 (0.1)    a   0.8  (0.2)
The mean size of lymphocyte populations was calculated based on their frequency as determined by fl  ow cytometry (Fig. 2). Total numbers (  
   10 6 ) are indicated (the SEM is 
shown in parentheses). Data are the mean of the number of mice indicated in parentheses after the mice genotypes. Values are the mean      the  SEM.
  a  P   
   0.05.
  b  P   
   0.001 versus control.2620 ROLE OF CYLD IN B CELLS | H  ö  velmeyer et al.
  CYLD  ex7/8     mice were also manifested in   CD19-Cre  /  CYLD  FL/FL     
mice, including a reduction in the percentage of transitional 
B cells, a reduction of immature B cells (  Fig. 5 C  ), and an 
increase in the total number of MZ B cells (  Fig. 5 D   and   Table I  ). 
Finally, in both   CD19-Cre  /  CYLD  FL/FL     and   CYLD  ex7/8     mice, 
the ratio of B-1 to B-2 B cells in the PC was inverted (  Fig. 5 E  ). 
Together, these data indicate that the B cell defects seen in the 
  CYLD  ex7/8     mice are cell autonomous. 
  Overexpression of sCYLD results in prolonged B cell survival 
  Bcl-2 transgenic mice exhibit enhanced B cell survival in vitro; 
this is associated with an increased size of secondary immune 
organs and B cell compartments in vivo (  22  ), which is simi-
lar to   CYLD  ex7/8     mice. To examine the survival capacities, 
B cells from   CYLD  ex7/8     and WT mice were cultured in en-
riched medium and monitored daily for survival by cell count-
ing and FACS analysis. The CYLD mutant B cells exhibited 
prolonged survival compared with WT B cells (  Fig. 6 A  , top).   
because of defects in other cell types. Therefore, we crossed 
  CYLD  FL/FL     mice to   CD19-Cre   mice (  20, 21  ), leading to Cre-
mediated excision of exon 7 of CYLD solely in B cells. The 
resulting mice,   CD19-Cre  /  CYLD  FL/FL     exhibited enlarged sec-
ondary immune organs, including spleen, LNs, and Peyer  ’  s 
patches similar to the  CYLD  ex7/8     mice that harbor the mutation 
in the germline (unpublished data). To analyze B cell develop-
ment in these mice, BM cells were stained for B220 and IgM. 
As seen in   Fig. 5 A   (top), BM cells of   CD19-Cre  /  CYLD  FL/FL     
mice show a small decrease in the percentage of immature cells, 
similar to BM of  CYLD  ex7/8     mice.  B220    IgM    	    cells were gated 
and analyzed for the expression of the pro-B cell marker, c-Kit. 
As for the   CYLD  ex7/8     mice, an accumulation of c-Kit  –  positive 
cells in the BM of   CD19-Cre  /  CYLD  FL/FL     was detected (  Fig. 
5 A  , bottom). Importantly, also in   CD19-Cre  /  CYLD  FL/FL     
mice, the total number of B cells was increased by two- to 
threefold (  Fig. 5 B   and   Table I  ) compared with WT mice. 
All other characteristics of the B lymphocytes detected in 
  Figure 4.     Serum immunoglobulin levels of   CYLD  ex7/8     mice. Sera from 8-wk-old   CYLD  ex7/8    mice  ( n    5) and WT littermates (  n    5) were analyzed by 
ELISA for various immunoglobulin levels. (A) Total immunoglobulin levels of   CYLD  ex7/8    and WT mice. (B) TD immune responses. 8-wk-old   CYLD  ex7/8    and  WT 
littermate mice were immunized with NP  28  -CG. Blood was taken at the indicated days after immunization. The NP-specifi  c antibody titers were analyzed 
by ELISA. (C) TI immune responses. 8-wk-old mice were immunized with NP-Ficoll. Blood was taken at the indicated days and analyzed for TI antibody 
isotypes with capture antigen NP  30  -BSA by ELISA. (D) FACS analysis of IgG1/IgM-positive B cells isolated from Peyer  ’  s patches with the indicated geno-
types. (E) Germinal center B cells from Peyer  ’  s patches of KLH-immunized mice with the indicated genotypes using cell surface markers for FAS/PNA 
(bottom). In D and E, cells were gated as CD19     lymphocytes negative for Topro3.     JEM VOL. 204, October 29, 2007 
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assessed by quantitative real-time PCR.   CYLD  ex7/8     B cells 
express fi  vefold more Bcl-2 mRNA compared with WT B 
cells (  Fig. 6 D  ). These results were further verifi  ed at protein 
level by intracellular staining with Bcl-2  –  specifi  c antibody 
(  Fig. 6 D  ). In addition, we found that primary fi  broblasts 
  isolated from   CYLD  ex7/8     mutant mice are more resistant to 
TNF    -induced apoptosis in the absence of protein synthesis 
(  Fig. 6 E  ). Therefore, it is tempting to speculate that the dele-
tion of the FL-CYLD, concomitant with the overexpression 
of sCYLD, conveys increased resistance to apoptosis, leading 
to the enlarged B cell compartment in   CYLD  ex7/8     mice. 
  Next, we determined the responses of   CYLD  ex7/8     and WT 
B cells to activating stimuli by incubating CFSE-labeled B cell 
cultures with optimal concentrations of anti-IgM F(ab)      2   and 
anti-CD40 antibodies, or with anti-RP105, LPS, or BAFF. 
As shown in   Fig. 6 F  , B cells from   CYLD  ex7/8     mice responded 
similarly to the diff  erent stimuli compared with WT B cells. 
Although the addition of BAFF to culture medium resulted in 
a more activated status of the mutant B cells compared with the 
WT B cells (  Fig. 6 B  ), supplementing the culture with BAFF 
together with LPS failed to increase proliferation (  Fig. 6 F  ). 
Therefore, we conclude that sCYLD contributes to the survival 
capacity of B cells, but does not aff  ect B cell proliferation. 
  Elevated expression of NF-    B and TRAF proteins in resting 
  CYLD  ex7/8     B cells 
  Previously, CYLD was shown to act on diff  erent proteins 
involved in the NF-    B (  7  –  9  ) and mitogen-activated protein 
kinase (MAPK) signaling pathways ( 17, 24 ). To study whether 
the enlargement of the B cell compartment in   CYLD  ex7/8     
After 4 d of culture, the number of living   CYLD  ex7/8     B cells was 
increased by twofold compared with WT B cells. Furthermore, 
the survival properties of   CYLD  ex7/8     B cells were compared 
with those of WT B cells cultured in medium supplemented 
with the B cell survival factor BAFF. BAFF treatment led 
to improved survival of both WT and mutant B cells (  Fig. 
6 A  , bottom). However, at all time points,   CYLD  ex7/8     B cells 
responded better to BAFF treatment compared with con-
trol B cells. Additionally, BAFF triggering of   CYLD  ex7/8     B 
cells resulted in the up-regulation of the activation markers 
CD40 and CD86, respectively, in comparison to WT B cells, 
whereas CpG treatment had similar eff  ects on both B cell 
cultures (  Fig. 6 B  ). To investigate whether the increased 
numbers of mature B cells in   CYLD  ex7/8     mice was related to 
response to BAFF in vivo, CYLD mutant and control mice 
were treated with either TACI- or human-Ig as control. It was 
shown that TACI-Ig blocks BAFF signaling, and that this 
treatment resulted in a dramatic decrease in B cell numbers (  23  ). 
In treated WT mice, we detected a signifi  cant decrease in 
the percentage of mature B cells in the mesenteric LN (  Fig. 
6 C   and Fig. S4 A, available at http://www.jem.org/cgi/
content/full/jem.20070318/DC1) and spleen (Fig. S4, B and C). 
In contrast, the percentage of B cells in   CYLD  ex7/8     mice was 
hardly aff  ected by the TACI-Ig treatment (  Fig. 6 C   and Fig. S4). 
No diff  erences in the total numbers of T cells in   CYLD  ex7/8     
and WT mice were observed upon TACI treatment, show-
ing that, indeed, TACI-Ig acts specifi  cally on B lymphocytes 
(unpublished data). 
  To investigate the increased viability of   CYLD  ex7/8     B cells 
in vitro, the expression of the antiapoptotic gene Bcl-2 was 
  Figure 5.     B cell  –  intrinsic phenotype of the   CYLD  ex7/8     mice. Flow cytometry analysis of cells from the BM, spleen, LN, and PC. Cells of 8-wk-old CD19-
Cre/  CYLD  FL/FL  ,   CYLD  ex7/8   , and WT controls, stained with the indicated antibodies. The genotypes of the mice shown are indicated on top of the fi  gure. (A) Analysis 
of BM populations. (bottom) Cells gated on Ig    	    lymphocytes. (B) B/T cell ratio of spleen cells. (C) Immature B cell populations in the spleen. IgM   CD23 	  
cells, which are defi  ned as transitional 1 (T1) cells, and IgM   CD23    B cells (T2/T3 and mature cells) are shown. (D) FACS analysis for spleen MZ B cells 
(CD21  high CD23 low  ). (E) B-1 and B-2 B cells in the PC of the indicated mice. Shown are all cells gated on the lymphocyte gate, excluding dead cells using Topro3. 
(B  –  D) All cells are further gated on CD19    . Data are representative of fi  ve independent experiments. Data were acquired and analyzed as described in   Fig. 3  .    2622 ROLE OF CYLD IN B CELLS | H  ö  velmeyer et al.
its processed form, p52, were only slightly increased (  Fig. 7 A  ). 
Furthermore, we could show that the RelB protein levels 
were also highly increased in the cytoplasm, as well as the 
nucleus, of   CYLD  ex7/8     B cells (  Fig. 7 B  ). The elevated pro-
tein levels of TRAF2, TRAF3, p100, RelB, and I    B     in 
  CYLD  ex7/8     B cells likely resulted from increased protein sta-
bility rather than from increased transcriptional activity, as 
quantitative real-time PCR revealed no signifi  cant diff  er-
ences in relative expression of these genes (Fig. S5, available 
at http://www.jem.org/cgi/content/full/jem.20070318/DC1). 
To investigate whether the noncanonical NF-    B pathway is 
aff  ected in   CYLD  ex7/8     B cells, purifi  ed B lymphocytes of con-
trol and   CYLD  ex7/8     mice were cultivated with optimal con-
centrations of BAFF for the indicated time points (  Fig. 7 C  ). 
mice results from alterations in the expression levels of pro-
teins involved in the NF-    B signaling pathway, whole-cell 
lysates of purifi  ed B cells from three   CYLD  ex7/8     mutant mice 
and three control mice were subjected to Western blot analy-
sis. This analysis revealed increased protein levels of TRAF2 
in the CYLD mutant B cells compared with WT B cells (  Fig. 
7 A  ).   Additionally, the protein levels of TRAF3 and NEMO 
were determined, showing that TRAF3 levels were increased, 
whereas NEMO levels were unchanged (  Fig. 7 A  ). The lev-
els of I    B     protein were markedly elevated in   CYLD  ex7/8     
B cells, although its phosphorylation on conserved serine res-
idues was unaltered. Most interestingly, NF    B2/p100 pro-
tein levels primarily involved in the noncanonical NF-    B 
pathway were dramatically increased, whereas the levels of 
  Figure 6.     In vitro stimulation and survival of   CYLD  ex7/8    B cells. (A) Purifi  ed (4   
   10 6 )   CYLD  ex7/8    and WT B cells were cultured in medium alone (with-
out stimulation) or in medium supplemented with 100     g BAFF. Numbers of surviving cells were determined by counting viable cells and by FACS analysis. 
Each time point represents the average of six samples      the SEM. (B) Expression of activation markers CD40 (left) and CD86 (right) before and after stim-
ulation of splenic B cells from the indicated genotypes with either BAFF or CpG. (C)   CYLD  ex7/8    and WT mice (  n    3) were treated twice a week for 1 wk 
with 20     g TACI-Ig or Hu-Ig control protein. Comparison of percentages of mesenteric LN B cells from mice treated with control Hu-Ig (  −  ) and TACI-Ig () 
is shown. Values are the mean      the SEM. *, P   
   0.05. (D) Relative expression of Bcl-2 from purifi  ed splenic B cells from mice of the indicated genotypes 
(  n    3) was determined by quantitative real-time PCR and intracellular staining. Values are the mean      the SEM. *, P   
   0.05. (E) TNF-induced apoptosis. 
Embryonic fi  broblasts isolated from mice of the indicated genotypes were pretreated with PMA or left untreated before induction of apoptosis by the 
simultaneous addition of TNF     and CHX. Shown is the percentage of dead (AnnexinV   Topro3   ) and apoptotic cells (AnnexinV   Topro3   	   ) from the total 
cells in the culture. (F) In vitro proliferation assay of purifi  ed splenic B cells from   CYLD  ex7/8    and WT control mice. B cells were isolated and loaded with 
CFSE. Thereafter, cells were triggered for 4 d with the indicated stimuli with and without BAFF. Shown are cells gated on lymphocyte and blast cell gate 
using Topro3 to exclude dead cells. Cells were further gated using CD45R (B220) surface marker.     JEM VOL. 204, October 29, 2007 
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(  Fig. 7 E  ). Nonstimulated   CYLD  ex7/8     B cells exhibited de-
tectable NF-    B activation, which was not observed in WT B 
cells (  Fig. 7 E  ). However, the NF-    B  –  activating response to 
anti-IgM was unaltered at the diff  erent time points of stimu-
lation in   CYLD  ex7/8     B cells compared with WT B cells. This 
result suggests that the basal activity of NF-    B may refl  ect an 
increased response to a yet unknown endogenous activator. 
  To estimate the eff  ect of the sCYLD in B cells on MAPK 
signaling, we performed cytometric bead assay (CBA) to de-
termine quantitatively phosphorylated MAPKs, which can 
be visualized using FACS analysis. In this assay, LPS stimula-
tion resulted in increased phosphorylation of MAPK p38 in 
  CYLD  ex7/8     B cells compared with WT B cells (  Fig. 7 F  ). 
Similar results were observed by Western blotting of anti-
BCR  –  stimulated B cells (  Fig. 7 G  ). In contrast, we observed 
At all time points analyzed, we found increased p100 levels, 
but no signifi  cant changes in the levels of its processed form, 
p52, in   CYLD  ex7/8     B cells when compared with controls 
(  Fig. 7 C  ). 
  To measure canonical NF-    B activity in   CYLD  ex7/8     B 
cells, splenic B cells were stimulated with anti-CD40, LPS, 
and anti-BCR (  Fig. 7 D  ). We did not observe signifi  cant dif-
ferences in I    B     degradation upon triggering of   CYLD  ex7/8     
and WT B cells with the aforementioned stimuli (  Fig. 7 D  ). 
Similarly, we did not detect changes in I    B degradation and 
phosphorylation after anti-BCR treatment (  Fig. 7 D  ). As a 
direct measure of NF-    B activity, we performed electropho-
retic mobility shift assay (EMSA) using NF-    B consensus-
binding oligonucleotides with nuclear extracts from resting 
B cells stimulated with optimal concentrations of anti-BCR 
  Figure 7.     Analysis of signal transduction of   CYLD  ex7/8     mutant splenic B cells. (A) Whole-cell extracts were examined by Western blot using anti-
bodies against the indicated proteins. Shown are three Western blots from B cell lysates of three different WT (lanes 1  –  3) and three different   CYLD  ex7/8   
(lanes 4  –  6) mice isolated in the same experiment. AKT-specifi  c antibody was used as loading control. (B; left) cytoplasmic and (right) nuclear extracts of 
nonactivated B cells isolated from the indicated genotypes were probed with RelB-specifi  c antibody. H2B and actin-specifi  c antibodies were used as load-
ing control. (C) MACS-purifi  ed B cells were rested for 4 h and subsequently stimulated with optimal concentrations of BAFF for the indicated time points 
and subjected to Western blot analysis using the indicated antibody. (D) Extracts from   CYLD  ex7/8    and WT B cells treated with an anti-CD40 antibody, LPS, 
or anti-BCR for different time points were analyzed with antibodies against I   B    and  pI  B  .  Actin-specifi  c antibody was used as loading control. 
(E) EMSA was performed with extracts of B cells rested for 4 h after isolation. Cells were then activated by anti-BCR for the indicated time points before 
extracts were prepared, incubated with NF-   B – specifi  c labeled probe, and separated on native PAGE. (F) B cell lysates from   CYLD  ex7/8    and WT controls 
were stimulated with LPS for the indicated time points, and CBA was performed using beads loaded with antibodies specifi  c for p-p38 and pERK1/2. 
(G) Western blot was performed for p-p38 and pERK from B cells of the indicated genotypes stimulated with anti-BCR for the indicated time points. Actin-
specifi  c antibody was used as loading control.     2624 ROLE OF CYLD IN B CELLS | H  ö  velmeyer et al.
reduced phosphorylation of ERK1 and ERK2 upon LPS 
stimulation (  Fig. 7 F  ). This could be further confi  rmed with 
Western blot analysis (  Fig. 7 G  ). 
  In keratinocytes isolated from   CYLD  ko     mice, Bcl-3 asso-
ciates with the NF-    B proteins p52 and p50 and promotes 
increased transactivation of   cyclin D1   compared with WT cells 
(  18  ). Although we have shown that sCYLD is able to interact 
with Bcl-3 and to remove K63-conjugated Ub, we were in-
terested to see whether Bcl-3 is present in the nuclei of B cells 
from   CYLD  ex7/8     mice without activation. To this end, we 
prepared cytospins of   CYLD  ex7/8    ,   CYLD  ex7/8;wt    ,   CYLD  ko    , and 
WT B cells.   Fig. 8   (  A and B)   demonstrates that Bcl-3 was 
predominantly located in the nucleus, or in close proximity 
to the nuclei, of untreated   CYLD  ex7/8     B cells, whereas in WT 
B cells, Bcl-3 was primarily found in the cytoplasm.   Calculat-
ing the percentage of B cells of the various genotypes con-
taining nuclear Bcl-3 revealed that 60% of the   CYLD  ex7/8     
B cells contain nuclear Bcl-3, whereas B cells from WT, 
  CYLD  ex7/8;wt    , and   CYLD  ko     exhibit 8, 3, and 2.5% of Bcl-3 in 
the nucleus, respectively (  Fig. 8 C  ). Furthermore, we could 
corroborate these results using Western blot analysis of ex-
tracts from   CYLD  ex7/8     mice (  Fig. 8 D  ). By quantitative real-
time PCR, we could show that the increased protein levels of 
Bcl-3 in the B cells of the   CYLD  ex7/8     mice are not a result of 
higher Bcl-3 gene expression (Fig. S5). Interestingly, mice 
that are defi  cient for CYLD do not show spontaneous trans-
location of Bcl-3 to the nucleus. These results are reminiscent 
of the previously published Bcl-3 transgenic mice (  25  ), in 
which overexpression of Bcl-3 in B cells resulted in lymph-
adenopathy, splenomegaly, and altered immunoglobulin pro-
duction, similar to what was observed in   CYLD  ex7/8     mice. 
    DISCUSSION   
  In this article, we report the function of a splice variant of 
CYLD devoid of the TRAF2 and NEMO binding sites. 
Expression of this shorter form of CYLD (sCYLD) with a 
simultaneous defi  ciency of the full-length (FL) protein gave 
rise to a dramatic accumulation of mature B lymphocytes in 
all secondary lymphoid organs in vivo. This B cell accumula-
tion is a consequence of increased survival, rather than in-
creased proliferation, putatively resulting from aggravated 
Bcl-2 expression caused by various alterations in signal trans-
duction pathways, such as NF-    B and MAPK signaling. In 
contrast, mice that are entirely devoid of CYLD (  CYLD  ko     
mice) do not show any abnormalities in the B cell compart-
ment. Therefore, we reason that sCYLD has other functions 
in B cell homeostasis than FL-CYLD. Under physiological 
conditions FL-CYLD expression might be diminished, 
whereas the expression of sCYLD is elevated. Indeed, we 
detected various expression levels of both CYLD forms in 
diff  erent tissues and cell types. Therefore, we suggest that also 
  Figure 8.     Bcl-3 accumulation in   CYLD  ex7/8    B cells. (A) Cytospins were 
prepared from B cells isolated from   CYLD  ex7/8  ,   CYLD  ex7/8;wt , CYLD ko   , and WT 
mice and immunostained with anti  –  Bcl-3 and counterstained with 
Hoechst 33258. Shown are unstimulated B cells (top) and B cells treated 
with anti-BCR (bottom). Bar, 5     m. (B) Same as in A, but showing more 
cells. Bar, 5     m. (C) Quantifi  cation of nuclear Bcl-3 from unstimulated B 
cell cytospins from the indicated genotypes. For each individual genotype, 
400 cells were counted and quantifi  ed for nuclear Bcl-3 localization. The 
frequency of nuclear Bcl-3 localization in   CYLD  ex7/8    B cells were statisti-
cally signifi  cant (P      0.001) compared with B cells isolated from WT, 
  CYLD  ex7/8;wt   , and   CYLD  ko    mice. (D) Lysates of MACS-purifi  ed B cells from 
the indicated genotypes subjected to Western blot analysis using Bcl-3 
antibody. Duplicates for each mouse strain are shown. Actin was used as 
a loading control.     
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as essential functions for these adaptor molecules in CD40-
induced class switch recombination and Ig production were 
reported (  31, 32  ). Indeed,   CYLD  ex7/8     B cells switch more 
effi   ciently to IgG1, but whether this is a result of the p38 hy-
peractivation observed in   CYLD  ex7/8     B cells or a result of im-
paired ERK activation still needs further investigation. 
  Furthermore,   CYLD  ex7/8     B cells exhibit a signifi  cant ac-
cumulation of Bcl-3 in the nucleus that cannot be explained 
by an inability of sCYLD to associate with Bcl-3, as we could 
show that sCYLD binds and removes K63-linked ubiquitin 
chains from Bcl-3. Western blot analysis of B lymphocytes 
using Bcl-3 antibody revealed aggravated Bcl-3 protein lev-
els, whereas on the RNA level, expression of Bcl-3 was un-
altered in   CYLD  ex7/8     B cells. Ultimately,   CYLD  ex7/8     mice 
show a very similar phenotype to mice overexpressing Bcl-3 
in B lymphocytes (  25  ). Both transgenic mice show lymph-
adenopathy and splenomegaly and exhibit distorted follicles 
in the spleen, resulting from an enlarged B cell compartment. 
Further, both mouse strains showed an increase in IgG1 and 
decreased levels of IgM and IgG3 in the sera compared with 
WT mice. In addition, enhanced B cell survival, accumula-
tion of MZ B cells, as well as increased B cell size, and the in-
creased expression of CD21/CD23 observed in   CYLD  ex7/8     
mice are also found in Bcl-3 transgenic mice. 
  The elevated expression of Bcl-2 in   CYLD  ex7/8     B cells may 
be a consequence of the dramatic overexpression of the NF-    B 
proteins p100 and RelB, which might activate transcription 
of Bcl-2 in a complex with Bcl-3 upon signaling through the 
noncanonical NF-    B pathway (  33  ). Thus, nuclear Bcl-3 in 
combination with p100 can induce the expression of Bcl-2 
(  33  ) and might account for the elevated B cell survival ob-
served in the   CYLD  ex7/8     mice, as shown previously for Bcl-2 
transgenic mice (  22, 34  ). Concomitantly,   CYLD  ex7/8     B cells 
are less dependent on BAFF signaling by a yet unsolved mech-
anism. This was demonstrated by ineff  ective BAFF blocking 
by TACI-Ig. Collectively, our data suggest that the newly 
identifi  ed splice variant sCYLD regulates B cell survival medi-
ated through a variety of signaling disarrangements. 
    MATERIALS AND METHODS   
  Generation of   CYLD   mutant mice.     The generation of CYLD mutant 
mice is described in the Supplemental materials and methods. All animal 
experiments were in accordance with the guidelines of the Central Animal 
Facility Institution of the University of Mainz. 
  RNA analysis.     For RNA analysis, total RNA was isolated using Trizol re-
agent (Invitrogen) according to the manufacturer  ’  s instruction. The follow-
ing primers were used for RT-PCR amplifi  cation of mouse   CYLD  : P1, 
5    -CTCAGACCCTGGAAGTAGAA-3    ; P2, 5    -TTGTAATGGCCCT-
GGATGCC-3    . Quantitative real-time PCR of Bcl-2, p100, RelB, IkB    , 
TRAF2, TRAF3, and Bcl-3 was performed using primers from QIAGEN, 
as described on their homepage (https://www1.qiagen.com/GeneGlobe/
Default.aspx). 
  Immunostaining of purifi  ed B cells.     Cytospins of purifi  ed B cells were 
fi  xed in acetone for 10 min at   −  20  °  C and stained for Bcl-3 according to 
standard methods, using polyclonal rabbit IgG Bcl-3 antibody. All incuba-
tion steps of the staining procedure were performed at room temperature. 
under normal conditions, the unique function of sCYLD can 
be manifested. 
  The CYLD-defi  cient mice generated by Reiley et al. (  26  ) 
demonstrate an elevated number of B lymphocyte, which is 
explained by a compensatory eff  ect caused by the reduction 
in the T-lymphocyte number (  26  ). In   CYLD  ex7/8     mutant 
mice, the generalized accumulation of mature B cells seems 
to be B cell intrinsic because   CD19-Cre/CYLD  FL/FL     mice, in 
which only the B cells express sCYLD and concomitantly 
lack the FL-CYLD protein, show a dramatically enlarged B 
cell compartment. We further observed that   CYLD  ex7/8     mice 
have an increased number of Ig    -positive B cells compared 
with WT mice. This might be caused by the partial block in 
B cell development, which is demonstrated by an increase in 
the number of c-Kit  –  positive B cells in the BM. A block dur-
ing B cell development may allow the developing B cells to 
edit their light chain locus, as seen in the process of B cell 
editing (  27  ), which, indeed, results in higher numbers of 
    -positive B cells. 
  We observed increased protein levels of several mole-
cules involved in the NF-    B signaling pathway in   CYLD  ex7/8     
B cells, including I    B    . However, the degradation and 
phosphorylation of I    B     is as effi   cient in the   CYLD  ex7/8     
B cells as in the WT B cells upon stimulation, showing that 
the canonical NF-    B activation is unaltered. Consistently, 
the relative expression of I    B    , p100, and RelB, which are 
all under the regulation of the NF-    B pathway, was unaltered 
as determined by quantitative real-time PCR, thus pointing 
to increased protein stability resulting from diff  erences in post-
translational modifi  cations. Nevertheless, EMSA revealed ele-
vated binding of nuclear transcription factors to the NF-    B 
consensus probe in unstimulated B cells. 
  We could demonstrate elevated protein levels of TRAF2 
and TRAF3 in   CYLD  ex7/8     B cells, which is a consequence of 
impaired posttranslational modifi  cation because relative ex-
pression revealed by real-time PCR was unaltered. Consis-
tently, TRAF2 was highly ubiquitinated in   CYLD  ex7/8     MEFs, 
presumably by K63-linked Ub chains, as shown by Western 
blot analysis. Therefore, it is tempting to speculate that K63-
ubiquitinated TRAF2 exhibit increased protein stability and 
possibly have impaired functionality. This is supported by 
the aggravated TRAF3 protein levels in   CYLD  ex7/8     B cells 
because TRAF2 was shown to be a negative regulator of 
TRAF3 upon stimulation with CD40 (  28  ). B lymphocytes 
defi  cient for TRAF2 demonstrate a phenotype similar to that 
of   CYLD  ex7/8     B cells with increased TRAF3 protein levels, 
but also show constitutive processing of p100 to p52, which 
is contrary to   CYLD  ex7/8     B cells (  29  ). In contrast, however, 
TRAF3-defi  cient cells also display constitutive processing of 
p100 to p52, resulting in embryonic lethality. This pheno-
type can be rescued in vivo by simultaneous defi  ciency of 
p100 (  30  ). Therefore, elevated TRAF3 levels should lead to 
increased p100 levels. Consistently,   CYLD  ex7/8     B cells exhibit 
increased p100 protein levels, but not elevated processing to 
p52. In addition, elevated TRAF2 and TRAF3 levels might 
promote MAPK p38-mediated isotype switching to IgG1, 2626 ROLE OF CYLD IN B CELLS | H  ö  velmeyer et al.
  Western blot.     To prepare whole-cell lysates, B cells were lysed in 1% Tri-
ton X-100 with protease inhibitors. MACS-purifi  ed B cells were prepared. 
Protein lysates (30     g) were separated by 10% SDS-PAGE and subsequently 
transferred to PVDF membranes. Protein blots were probed with anti-
bodies to phospho-I    B    , I    B    , phospho-ERK, ERK, phospho-p38, p38, 
p100, and Bcl-2 (all from Cell Signaling Technology), Bcl-3, NEMO, 
TRAF2, TRAF3, and RelB (from Santa Cruz Biotechnology), and with 
antibodies to actin (Sigma-Aldrich), AKT, or H2B (Cell Signaling Tech-
nology) as internal loading controls. CYLD-specifi  c antibodies were pre-
pared by immunization of rabbits with recombinant CYLD fragments. 
Nuclear extracts were prepared using high-salt buff  er, and proteins were 
subjected to Western blotting. CBA was performed according to the man-
ufacturer  ’  s guidelines. 
  Statistical analysis.     Values are presented as the means      the SEM or SD, 
with the number of independent experiments. Statistical diff  erences were 
determined using the Student  ’  s   t   test. 
  Online supplemental material.     Fig. S1 shows the targeting strategy to 
generate the   CYLD  ex7/8     mice. Fig. S2 describes the B cell population of 
  CYLD  ko     mice. Fig. S3 describes the KLH-specifi  c immune responses of 
  CYLD  ex7/8     mice and class switch recombination in culture. Fig. S4 shows the 
B cell populations in   CYLD  ex7/8     mice treated with TACI-Ig and Fig. S5 
summarizes the relative RNA expression of diff  erent molecules using real 
time PCR. The online version of this article is available at http://www.jem
.org/cgi/content/full/jem.20070318/DC1. 
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